Kenneth Civello, MD
Clinical Cardiac Electrophysiology · Baton Rouge, LANPI 1699745562
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 66.5% of it on its own, with 46 other manufacturers making up the rest. Reporting peaked in 2019 at $13,030 and has fallen 92.5% since, to $980 in 2025.
Across 445 payments — averaging $66.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$20K
- Atricure, Inc.$3K
- Boston Scientific$1K
- Johnson & Johnson$924
- Pfizer$690
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$464
- plus $3K from 41 others
Across 47 payments — averaging $842.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$17K
- Atricure, Inc.$10K
- Medical Device Business Services, Inc.$7K
- Abbott$5K
What the payments were for
- Consulting fees$2,1007%
- Speaking & faculty fees$12,70043%
- Travel & lodging$4,20514%
- Food & beverage$10,53236%
- Education$140%
- Other$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EPI-SENSE GUIDED COAGULATION SYS$2,803
- Arctic Front$1,937
- Watchman$833
- ATRICURE SYNERGY ABLATION SYSTEM$145
- NA$119
- Achieve$119
How this compares
$29,568 in reported general payments places this provider in the 65th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.
See all clinical cardiac electrophysiology providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 580 | $640,309 |
| XareltoRivaroxaban | 146 | $166,404 |
| OpsumitMacitentan | 12 | $144,544 |
| JardianceEmpagliflozin | 135 | $127,145 |
| EntrestoSacubitril/Valsartan | 75 | $84,363 |
| Repatha SureclickEvolocumab | 95 | $69,221 |
| MultaqDronedarone Hcl | 27 | $36,080 |
| Dofetilide | 143 | $24,824 |
| FarxigaDapagliflozin Propanediol | 22 | $20,142 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $9,916 |
| Flecainide Acetate | 179 | $9,508 |
| Metoprolol Succinate | 441 | $8,729 |
| Atorvastatin Calcium | 319 | $4,485 |
| Acebutolol Hcl | 50 | $3,651 |
| Amiodarone Hcl | 46 | $2,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $690 | $640,309580 claims |
| Johnson & JohnsonXarelto | $924 | $166,404146 claims |
| Boehringer IngelheimJardiance | $38 | $127,145135 claims |
| NovartisEntresto | $383 | $84,36375 claims |
| Sanofi-aventis U.S. LLCMultaq | $129 | $36,08027 claims |
| AstraZenecaFarxiga | $152 | $20,14222 claims |
| Esperion Therapeutics, Inc.Nexlizet | $19 | $9,91613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.
Other clinical cardiac electrophysiology in Baton Rouge
- Mark PolletBaton Rouge$90K
- Joshua AymondBaton Rouge$64K
- Thomas GullattBaton Rouge$31K
- Charles SmithBaton Rouge$29K
- Robert DrennanBaton Rouge$18K
- Paul DampfBaton Rouge$12K
- Wenjie XuBaton Rouge$10K
- Norman DeumiteBaton Rouge$9K
- Henry PatrickBaton Rouge$4K
- Nassir MarroucheNew Orleans$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.